iShares U.S. Healthcare ETF News - August 9, 2026

AstraZeneca eyes Bristol Myers merger, creating $400B oncology powerhouse

AstraZeneca is discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal would value the combined pharmaceutical giant at nearly $400...